CorMedix Inc. (CRMD) stock
CRMDNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 13/30
$5.08+0.58 (+12.89%)
Close on Nov 19, 2026Market cap $395.96MP/E –Yield –
CorMedix shares outstanding
Diluted shares outstanding: the weighted share count used for earnings per share, adjusted for stock splits.
CorMedix's shares outstanding was 92M at Jun 30, 2026. For fiscal 2025 it was 0M, up 36.4% from the year before. Over ten years it grew -44.9% a year on average. The highest annual figure on record is 55M in fiscal 2017.
Annual shares outstanding
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0M | +36.4% |
| FY2024 | Dec 31, 2024 | 0M | -99.9% |
| FY2023 | Dec 31, 2023 | 51M | +26.4% |
| FY2022 | Dec 31, 2022 | 40M | +6.9% |
| FY2021 | Dec 31, 2021 | 38M | +31.9% |
| FY2020 | Dec 31, 2020 | 29M | +18.3% |
| FY2019 | Dec 31, 2019 | 24M | +35.6% |
| FY2018 | Dec 31, 2018 | 18M | -67.7% |
| FY2017 | Dec 31, 2017 | 55M | +45.2% |
| FY2016 | Dec 31, 2016 | 38M | +21.1% |
| FY2015 | Dec 31, 2015 | 31M | +46.2% |
| FY2014 | Dec 31, 2014 | 21M | +55.1% |
| FY2013 | Dec 31, 2013 | 14M | +21.2% |
| FY2012 | Dec 31, 2012 | 11M | 0.0% |
| FY2011 | Dec 31, 2011 | 11M | – |
Quarterly shares outstanding
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | 92M | +34.1% |
| Q1 FY2026 | Mar 31, 2026 | 93M | +58.1% |
| Q3 FY2025 | Sep 30, 2025 | 86M | +49.6% |
| Q2 FY2025 | Jun 30, 2025 | 72M | +25.1% |
| Q1 FY2025 | Mar 31, 2025 | 69M | +20.0% |
| Q3 FY2024 | Sep 30, 2024 | 59M | +4.0% |
| Q2 FY2024 | Jun 30, 2024 | 58M | +27.0% |
| Q1 FY2024 | Mar 31, 2024 | 58M | +30.4% |
| Q4 FY2023 | Dec 31, 2023 | 57M | +37.2% |
| Q3 FY2023 | Sep 30, 2023 | 57M | +37.3% |
| Q2 FY2023 | Jun 30, 2023 | 45M | +14.1% |
| Q1 FY2023 | Mar 31, 2023 | 44M | +15.3% |
| Q4 FY2022 | Dec 31, 2022 | 42M | +9.8% |
| Q3 FY2022 | Sep 30, 2022 | 41M | +8.1% |
| Q2 FY2022 | Jun 30, 2022 | 40M | +4.4% |
| Q1 FY2022 | Mar 31, 2022 | 38M | +5.3% |
| Q4 FY2021 | Dec 31, 2021 | 38M | +17.6% |
| Q3 FY2021 | Sep 30, 2021 | 38M | +28.8% |
| Q2 FY2021 | Jun 30, 2021 | 38M | +45.7% |
| Q1 FY2021 | Mar 31, 2021 | 36M | +39.4% |
| Q4 FY2020 | Dec 31, 2020 | 32M | +26.2% |
| Q3 FY2020 | Sep 30, 2020 | 30M | +23.3% |
| Q2 FY2020 | Jun 30, 2020 | 26M | +9.7% |
| Q1 FY2020 | Mar 31, 2020 | 26M | +12.9% |
| Q4 FY2019 | Dec 31, 2019 | 26M | +22.7% |
| Q3 FY2019 | Sep 30, 2019 | 24M | +27.5% |
| Q2 FY2019 | Jun 30, 2019 | 24M | +44.7% |
| Q1 FY2019 | Mar 31, 2019 | 23M | +53.1% |
| Q4 FY2018 | Dec 31, 2018 | 21M | -68.7% |
| Q3 FY2018 | Sep 30, 2018 | 19M | -68.8% |
| Q2 FY2018 | Jun 30, 2018 | 16M | -68.7% |
| Q1 FY2018 | Mar 31, 2018 | 15M | -62.9% |
| Q4 FY2017 | Dec 31, 2017 | 67M | +165446.5% |
| Q3 FY2017 | Sep 30, 2017 | 60M | +54.4% |
| Q2 FY2017 | Jun 30, 2017 | 53M | – |
| Q1 FY2017 | Mar 31, 2017 | 41M | – |
| Q4 FY2016 | Dec 31, 2016 | 0M | – |
| Q3 FY2016 | Sep 30, 2016 | 39M | – |
See a number that looks wrong?